David Simpson

77 papers receiving 7.5k citations

David Simpson's Hit Papers

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL 2019 · 303 citations
3030+5+10Years since publication4008001.2k

Peers

David Simpson
Comparison fields: 5 of 93
  • Genetics 2.6k
  • Pathology and Forensic Medicine 2.1k
  • Hematology 1.4k
  • Oncology 1.2k
  • Rheumatology 362
Replace Roger Dansey with:
Roger Dansey United States
Devinder Singh Gill Australia
Pierre Morel France
Enrico Maria Pogliani Italy
Martin Grießhammer Germany
Luis F. Porrata United States
Jeffrey Matous United States
Michel Leporrier France
Jun Zhu China
Farrukh Tauseef Awan United States
David Simpson relative to Roger Dansey United States Roger Dansey's profile →
Citations per field
00.5×2×2.7×
Roger Dansey · 1×
Citations per year

Countries citing papers authored by David Simpson

Since Specialization
Citations

This map shows the geographic impact of David Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Simpson more than expected).

Fields of papers citing papers by David Simpson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Simpson. The network helps show where David Simpson may publish in the future.

Co-authors

The 25 scholars most cited alongside David Simpson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Simpson Line = papers co-authored together David Simpson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Hit paper breakdown →
20151301
2
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Hit paper breakdown →
2010844
3
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Hit paper breakdown →
2019521
4
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Hit paper breakdown →
2014517
5 2017448
6
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Hit paper breakdown →
2019387
7 2014363
8
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Hit paper breakdown →
2019303
9 2018299
10 2016229
11 2019228
12 2017226
13 2019221
14 2019216
15 2019211
16 2018123
17 202095
18 202095
19 202186
20 201882

About David Simpson

David Simpson is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Transplantation, having authored 77 papers that have together received 7.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (19 papers), Multiple Myeloma Research and Treatments (9 papers), Viral-associated cancers and disorders (7 papers), Hematopoietic Stem Cell Transplantation (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Renal Transplantation Outcomes and Treatments (1 paper) and T-cell and B-cell Immunology (1 paper). The work is most often cited by research in Genetics (2.6k citations), Pathology and Forensic Medicine (2.1k citations), Hematology (1.4k citations), Oncology (1.2k citations) and Rheumatology (362 citations). David Simpson has collaborated with scholars based in United States, New Zealand and Australia. Frequent co-authors include Samar Issa, Patrick Wood, David A. Macdonald, John M. Burke, Kathryn S. Kolibaba, Ian W. Flinn, Brad S. Kahl, Richard van der Jagt, Doreen M. Hallman and Judith Trotman. Their work appears in journals such as Blood, Hematological Oncology, Haematologica, British Journal of Haematology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact